The Zhitong Finance App learned that Morgan Stanley released a research report stating that it identifies and previews potential catalysts that may affect the stock price of the Chinese biotech stock industry in the fourth quarter of 2026, and the industry rating is “attractive.”

On the side of Heyu-B (02256), if the annual growth rate of higher doses of ABSK061 exceeds the initial annual growth rate of 2.4 cm and at the same time, phosphate and corneal toxicity remain low, the bank is optimistic about upward space.

In terms of Cinda Biotech (01801), the bank expects mazdutide to be superior to semaglutide in terms of weight loss and liver fat, but the advantages must be sufficient to rationalize more gastrointestinal discomfort.

On the side of Conoa-B (02162), the bank is optimistic about CM512's strategy for nasal polyps every 24 weeks; if the improvement in pulmonary function continues between doses, it will reinforce its asthma differentiation.

On the side of Nuochengjianhua (09969), the success of the third phase of ICP-332 is well known; until longer infection and blood count data are lacking, the bank is still cautious about TYK2 safety premiums.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.